2-hydroxy-9Z,12Z-octadecadienoic acid, ABTL-0812, ABTL0812, alpha-hydroxylinoleic acid
| Name | alpha-Hydroxylinoleic acid | ||
| PubChem CID | 21158511 | ||
| Molecular Weight | 296.4g/mol | ||
| Synonyms |
2-hydroxy-9Z,12Z-octadecadienoic acid, ABTL-0812, ABTL0812, alpha-hydroxylinoleic acid |
||
| Formula | C₁₈H₃₂O₃ | ||
| SMILES | CCCCCC=CCC=CCCCCCCC(C(=O)O)O | ||
| InChI | 1S/C18H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h6-7,9-10,17,19H,2-5,8,11-16H2,1H3,(H,20,21)/b7-6-,10-9- | ||
| InChIKey | AFDSETGKYZMEEA-HZJYTTRNSA-N | ||
| CAS Number | 57818-44-7 | ||
| ChEBI ID | CHEBI:136927 | ||
| Drug Bank ID | DB16027 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | GuaLi | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Malvales
-->Family: Malvaceae
-->Genus: Pachira
-->Species: Pachira aquatica
|
||
| Pair Name | alpha-Hydroxylinoleic acid, Paclitaxel | |||
| Partner Name | Paclitaxel | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Down-regulation | Expression | MAP1LC3A | hsa84557 |
| Up-regulation | Expression | MAP1LC3B | hsa81631 | |
| Up-regulation | Phosphorylation | PRKAA1 | hsa5562 | |
| Down-regulation | Expression | AKT1 | hsa207 | |
| Up-regulation | Expression | TRIB3 | hsa57761 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 | |
| NCI-H157 | Lung squamous cell carcinoma | Homo sapiens (Human) | CVCL_0463 | |
| NCI-H520 | Lung squamous cell carcinoma | Homo sapiens (Human) | CVCL_1566 | |
| Result | The safety profile of ABTL0812 and its good synergy with chemotherapy potentiate the therapeutic potential of current lines of treatment based on chemotherapy regimens, arising as a promising option for improving these patients therapeutic expectancy. | |||
| Pair Name | alpha-Hydroxylinoleic acid, Paclitaxel | |||
| Partner Name | Paclitaxel | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Down-regulation | Expression | MAP1LC3A | hsa84557 |
| Up-regulation | Expression | MAP1LC3B | hsa81631 | |
| Up-regulation | Expression | TRIB3 | hsa57761 | |
| In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
| Result | ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models. | |||
| No. | Title | Href |
|---|---|---|
| 1 | The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. Int J Cancer. 2020 Aug 15;147(4):1163-1179. doi: 10.1002/ijc.32865. | Click |
| 2 | ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models. Cancer Commun (Lond). 2022 Jun;42(6):567-571. doi: 10.1002/cac2.12282. | Click |
